ReGenXBio

REGENX Biosciences develops therapeutic and research tools based on adeno-associated virus (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated virus vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, blood disorders, eye diseases, and neurodegenerative diseases. Additionally, it provides researchers with customized products and services, including AAV plasmids, AAV vector reporter systems, and custom AAV vectors.